Ken Griffin Imv Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.47 - $0.75 $21,677 - $34,591	-46,122 Reduced 81.47%	10,487 $6,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.45 $23,518 - $60,897	41,998 Added 287.44%	56,609 $37,000
Q1 2022 May 16, 2022	SELL	$1.07 - $1.5 $75,342 - $105,621	-70,414 Reduced 82.82%	14,611 $21,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.78 $72,130 - $105,238	59,123 Added 228.26%	85,025 $103,000
Q3 2021 Nov 15, 2021	BUY	$1.35 - $2.16 $15,337 - $24,539	11,361 Added 78.13%	25,902 $43,000
Q2 2021 Aug 16, 2021	BUY	$2.12 - $3.24 $9,079 - $13,876	4,283 Added 41.75%	14,541 $31,000
Q3 2020 Nov 16, 2020	SELL	$2.87 - $5.95 $6,621 - $13,726	-2,307 Reduced 18.36%	10,258 $46,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $4.5 $34,553 - $56,542	12,565 New	12,565 $37,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.